Johnson & Johnson's Net Income Jumps 18.2% in Q2 2025

Johnson & Johnson reported robust financial results for Q2 2025, with worldwide revenue reaching $23.74 billion, marking a 5.8% increase from Q2 2024's $22.45 billion. Net earnings for the quarter also saw a significant rise, climbing 18.2% to $5.54 billion compared to $4.69 billion in the same period last year. Diluted net earnings per share increased 18.7% to $2.29 from $1.93.

Innovative Medicine Segment Performance

The Innovative Medicine segment contributed significantly to the company's growth, with worldwide sales of $15.20 billion, a 4.9% increase. This growth was particularly driven by the Oncology franchise, which saw a 24.0% increase in worldwide sales to $6.31 billion. Key products like DARZALEX and ERLEADA reported substantial gains of 23.0% and 23.4% respectively, while newer oncology treatments like TALVEY and TECVAYLI experienced even higher growth rates.

MedTech Segment Highlights

The MedTech segment also demonstrated strong performance, with worldwide sales growing 7.3% to $8.54 billion. The Cardiovascular franchise was a standout, with sales surging 23.5% to $2.31 billion, primarily propelled by the acquisition of Shockwave, which contributed $292 million in sales. The Surgery and Vision segments also reported increases of 2.7% and 6.5% respectively, while Orthopaedics experienced a slight decrease of 0.3%.

Geographic and Operational Drivers

From a geographic perspective, the U.S. market showed strong performance, with sales increasing 7.8% to $13.54 billion. International sales grew 3.2% to $10.20 billion. Operationally, the company's worldwide sales growth was 4.6%, excluding the impact of currency fluctuations, and 3.0% when excluding acquisitions and divestitures, highlighting solid underlying business momentum across both Innovative Medicine and MedTech segments.